Multimarker Prediction of Coronary Heart Disease Risk. The Women's Health Initiative

Journal of the American College of Cardiology

Volumn 55, Issue 19, 2010, Pages 2080-2091

  Kim, Hyeon Chang ^a,b   Greenland, Philip ^a   Rossouw, Jacques E ^c   Manson, JoAnn E ^d   Cochrane, Barbara B ^e   Lasser, Norman L ^f   Limacher, Marian C ^g   Lloyd Jones, Donald M ^a   Margolis, Karen L ^h   Robinson, Jennifer G ⁱ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Yonsei University   (South Korea)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

Author keywords

biomarker; coronary heart disease; prediction

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; D DIMER; HOMOCYSTEINE; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; PLACEBO; VON WILLEBRAND FACTOR;

ADULT; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY RISK; FEMALE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEX FACTORS;

EID: 77951626147     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.12.047     Document Type: Article

References (76)

1. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
2. D'Agostino Sr. R.B., Grundy S., Sullivan L.M., and Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286 (2001) 180-187
3. Cushman M., Lemaitre R.N., Kuller L.H., et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 19 (1999) 493-498
4. Mangoni A.A., and Jackson S.H.D. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 112 (2002) 556-565
5. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
6. Chambless L.E., Folsom A.R., Sharrett A.R., et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 56 (2003) 880-890
7. Koenig W., Lowel H., Baumert J., and Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109 (2004) 1349-1353
8. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
9. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
10. Danesh J., Lewington S., Thompson S.G., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294 (2005) 1799-1809
11. Shlipak M.G., Sarnak M.J., Katz R., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 (2005) 2049-2060
12. Zethelius B., Johnston N., and Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 113 (2006) 1071-1078
13. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006) 2631-2639
14. Folsom A.R., Chambless L.E., Ballantyne C.M., et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk In Communities study. Arch Intern Med 166 (2006) 1368-1373
15. Ridker P.M., Buring J.E., Rifai N., and Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297 (2007) 611-619
16. Zethelius B., Berglund L., Sundstrom J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358 (2008) 2107-2116
17. Bray P.F., Larson J.C., Lacroix A.Z., et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 101 (2008) 1599-1605
18. Rossouw J.E., Cushman M., Greenland P., et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. Arch Intern Med 168 (2008) 2245-2253
19. Pradhan A.D., Manson J.E., Rossouw J.E., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288 (2002) 980-987
20. McGeechan K., Macaskill P., Irwig L., Liew G., and Wong T.Y. Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide. Arch Intern Med 168 (2008) 2304-2310
21. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
22. Anderson G.L., Manson J., Wallace R., et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 13 (2003) S5-S17
23. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
24. Hsia J., Langer R.D., Manson J.E., et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 166 (2006) 357-365
25. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
26. Curb J.D., McTiernan A., Heckbert S.R., et al. Outcomes ascertainment and adjudication methods in the women's health initiative. Ann Epidemiol 13 (2003) S122-S128
27. Rautaharju P.M., Park L.P., Chaitman B.R., Rautaharju F., and Zhang Z.M. The Novacode criteria for classification of ECG abnormalities and their clinically significant progression and regression. J Electrocardiol 31 (1998) 157-187
28. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837-845
29. Cook N.R. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115 (2007) 928-935
30. Pencina M.J., D'Agostino Sr. R.B., D'Agostino Jr. R.B., and Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008) 157-172
31. Wald N.J., Morris J.K., and Rish S. The efficacy of combining several risk factors as a screening test. J Med Screen 12 (2005) 197-201
32. Shlipak M.G., Fried L.F., Cushman M., et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293 (2005) 1737-1745
33. St-Pierre A.C., Cantin B., Bergeron J., et al. Inflammatory markers and long-term risk of ischemic heart disease in men: a 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis 182 (2005) 315-321
34. Ridker P.M., Paynter N.P., Rifai N., Gaziano J.M., and Cook N.R. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118 (2008) 2243-2251
35. Melander O., Newton-Cheh C., Almgren P., et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302 (2009) 49-57
36. de Lemos J.A., and Lloyd-Jones D.M. Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med 358 (2008) 2172-2174
37. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107 (2003) 391-397
38. Everett B.M., Kurth T., Buring J.E., and Ridker P.M. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am Coll Cardiol 48 (2006) 2235-2242
39. May M., Lawlor D.A., Brindle P., Patel R., and Ebrahim S. Cardiovascular disease risk assessment in older women: can we improve on Framingham?. British Women's Heart and Health prospective cohort study. Heart 92 (2006) 1396-1401
40. Pischon T., Hu F.B., Rexrode K.M., Girman C.J., Manson J.E., and Rimm E.B. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 197 (2008) 392-399
41. van der Meer I.M., de Maat M.P., Kiliaan A.J., van der Kuip D.A., Hofman A., and Witteman J.C. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 163 (2003) 1323-1328
42. Wilson P.W., Nam B.H., Pencina M., D'Agostino Sr. R.B., Benjamin E.J., and O'Donnell C.J. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 165 (2005) 2473-2478
43. Cook N.R., Buring J.E., and Ridker P.M. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145 (2006) 21-29
44. Shah T., Casas J.P., Cooper J.A., et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 38 (2009) 217-231
45. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., and Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359 (2008) 1897-1908
46. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
47. Woodward M., Rumley A., Welsh P., MacMahon S., and Lowe G. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost 5 (2007) 1795-1800
48. Fraser A., May M., Lowe G., et al. Interleukin-6 and incident coronary heart disease: results from the British Women's Heart and Health Study. Atherosclerosis 202 (2009) 567-572
49. Danesh J., Kaptoge S., Mann A.G., et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5 (2008) e78
50. Heinrich P.C., Castell J.V., and Andus T. Interleukin-6 and the acute phase response. Biochem J 265 (1990) 621-636
51. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
52. Rattazzi M., Puato M., Faggin E., Bertipaglia B., Zambon A., and Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?. J Hypertens 21 (2003) 1787-1803
53. Danesh J., Collins R., Appleby P., and Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279 (1998) 1477-1482
54. Malik I., Danesh J., Whincup P., et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358 (2001) 971-976
55. Madjid M., Awan I., Willerson J.T., and Casscells S.W. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 44 (2004) 1945-1956
56. Lowe G.D.O. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 3 (2005) 1618-1627
57. Margolis K.L., Manson J.E., Greenland P., et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative observational study. Arch Intern Med 165 (2005) 500-508
58. Welsh P., Whincup P.H., Papacosta O., et al. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. Q J Med 101 (2008) 785-791
59. Thaulow E., Erikssen J., Sandvik L., Stormorken H., and Cohn P.F. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 84 (1991) 613-617
60. Folsom A.R., Wu K.K., Rosamond W.D., Sharrett A.R., and Chambless L.E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 96 (1997) 1102-1108
61. Tracy R.P., Arnold A.M., Ettinger W., Fried L., Meilahn E., and Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 19 (1999) 1776-1783
62. Danesh J., Whincup P., Walker M., et al. Fibrin d-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 103 (2001) 2323-2327
63. Lowe G.D., Danesh J., Lewington S., et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 25 (2004) 252-259
64. Smith A., Patterson C., Yarnell J., Rumley A., Ben-Shlomo Y., and Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke?. The Caerphilly Study. Circulation 112 (2005) 3080-3087
65. Lowe G.D.O., Rumley A., McMahon A.D., et al. Interleukin-6, fibrin d-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 24 (2004) 1529-1534
66. Folsom A.R., Aleksic N., Park E., Salomaa V., Juneja H., and Wu K.K. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 21 (2001) 611-617
67. Danesh J., Collins R., and Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102 (2000) 1082-1085
68. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288 (2002) 2015-2022
69. Sarwar N., Sattar N., Gudnason V., and Danesh J. Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. Eur Heart J 28 (2007) 2491-2497
70. McGeechan K., Liew G., Macaskill P., et al. Risk prediction of coronary heart disease based on retinal vascular caliber (from the Atherosclerosis Risk In Communities [ARIC] study). Am J Cardiol 102 (2008) 58-63
71. Pepe M.S., Janes H., Longton G., Leisenring W., and Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159 (2004) 882-890
72. Ware J.H. The limitations of risk factors as prognostic tools. N Engl J Med 355 (2006) 2615-2617
73. Janes H., Pepe M.S., and Gu W. Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 149 (2008) 751-760
74. Hosmer D.W., and Lemeshow S. Applied Logistic Regression. 2nd edition (2000), John Wiley, New York, NY
75. Morrow D.A., Cannon C.P., Jesse R.L., et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115 (2007) e356-e375
76. Eggers K.M., Lagerqvist B., Venge P., Wallentin L., and Lindahl B. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 54 (2009) 357-364